Targeting Lipids

Inactive Publication Date: 2009-10-01
TEKMIRA PHARMA CORP
View PDF10 Cites 116 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0031]The present invention further includes methods of preparing lipid particles and pharmaceutical compositions, as well as kits useful in the preparation of these lipid particle and pharmaceutical compositions. The method includes providing a composition that includes an agent, e.g. an oligonuc

Problems solved by technology

However, many of these techniques are limited by the types of cells in which transmembrane transport is enabled and by the conditions needed for achieving such transport.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Targeting Lipids
  • Targeting Lipids
  • Targeting Lipids

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Carbohydrate Building Blocks for Conjugation

[0405]

[0406]Preparation of 101: Galactosamine pentaacetate 100 (52.00 g, 133.63 mmol) was taken in dichloroethane (300 mL) at ambient temperature. TMSOTf (44.55 g, 200.44 mmol) was added that and the mixture stirred at 50 C for 90 minutes in a water bath, heating stopped and the mixture stirred overnight at room temperature. It was poured in to an ice cold sodium bicarbonate solution; extracted with dichloromethane, washed with water and dried over sodium sulfate. Solvents were removed the residue dried under high vacuum overnight to get the compound as dark gum (44.50 g, quantitative). It was used for next reaction with out any further purification. 1H NMR and MALDI confirmed the product formation. MS: Calculated for C14H19NO8, 329.11; Found 352.1 (M+Na).

[0407]Preparation of 102: Compound 101 (43.70 g, 133.56 mmol) and the benzyl ester (41.71 g, 200.34 mmol) were dissolved in dichloroethane (300 mL), molecular sieves (50 g) w...

example 2

Synthesis of Pteroic Acid Precursors for Conjugation

[0438]Appropriately substituted pteroic acid precursor 110 was prepared as follows.

[0439]Synthesis of 4-[(2-isobutyrylamino-4-oxo-3,4-dihydro-pteridin-6-ylmethyl)-(2,2,2-trifluoroacetyl)-amino]benzoic acid 152. To a suspension of pteroic acid (25 g, 61.2 mmol) and DMAP (11.25 g, 92 mmol) in anhydrous pyridine (400 mL), TBDPS chloride (42 g, 153 mmol) was added. The reaction mixture was stirred at room temperature for 30 h after which isobutric anhydride (14.6 g, 92 mmol) was added and the mixture was slightly warmed. An additional 60 mL of pyridine was also added and the reaction mixture was stirred at room temperature overnight. The reaction mixture became homogenous after which pyridine and other volatiles were concentrated in a rotary evaporator. The residue was stirred with EtOAc (1 L) and acetic acid (100 mL) and water (500 mL) for 24 h. The thus obtained slurry was filtered, the residue was washed with water (500 mL), EtOAc (...

example 3

Synthesis of Lipid Conjugates

[0458]

[0459]Preparation of 201: 1, 2-Dioctadecyl sn glycerol (8.50 g, 14.23 mmol) and DSC (5.47 g, 1.5 eq.) were dissolved in DCM (100 mL) and cooled in an ice-water bath. Triethylamine (6.00 mL, 44 mmol) was added and stirred the mixture overnight. The mixture was transferred to a separatory funnel diluted with DCM, washed with bicarbonate solution and water. DCM layer separated and dried over sodium sulfate. Solvents were removed and the residue dried under high vacuum overnight. It was used for the next reaction with out further purification (Yield, 11.50 g).

[0460]Preparation of 202: Compound 201 (4.00 g, 5.42 mmol) and 6-aminohexanoate hydrochloride (1.477 g, 1.5 eq.) were dissolved in DCM and cooled in an ice bath. Pyridine (5 mL) was added to the mixture and stirred overnight. Solvents were removed and the residue dried under high vacuum. The residue extracted with dichloromethane, washed with bicarbonate and water. Crude product was purified by ch...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Structureaaaaaaaaaa
Degradation propertiesaaaaaaaaaa
Login to view more

Abstract

The present invention provides targeting lipids of structureL100—linker—L101   (CI),where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

Description

RELATED APPLICATIONS[0001]This application claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 60 / 992,309, filed Dec. 4, 2007; U.S. Provisional Patent Application Ser. No. 61 / 013,597 field Dec. 13, 2007; U.S. Provisional Patent Application Ser. No. 61 / 127,751, filed May 14, 2008; U.S. Provisional Patent Application Ser. No. 61 / 091,093, filed Aug. 22, 2008; and U.S. Provisional Patent Application Ser. No. 61 / 097,261, filed Sep. 16, 2008. The contents of all of these prior applications are hereby incorporated by reference in their entireties.GOVERNMENT SUPPORT[0002]The work described herein was carried out, at least in part, using funds from the United States government under contract number HHSN266200600012C from the National Institute of Allergy and Infectious Diseases / National Institutes of Health / Department of Health and Human Services (NIAID / NIH / DHHS) and contract number HDTRA-1-07-C-0082, from the Department of Defense and Defense Threat Reduction Agen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/713C07K14/00A61K47/42A61K31/7088C07K7/04C07K5/04A61K47/12
CPCA61K47/48092A61K47/48215C07H21/02A61K47/28A61K31/713A61K47/16A61K47/22A61K31/7088Y02P20/55A61K47/549A61K31/7004A61K31/7052A61K31/70A61P25/00A61P35/00A61P3/06A61P37/02A61P3/10Y02A50/30A61K47/554A61K47/56A61K47/60A61K47/543A61K48/00
Inventor MANOHARAN, MUTHIAHRAJEEV, KALLANTHOTTATHIL G.NARAYANANOVAIR, GAYAPRAKASH K.JAYARAMAN, MUTHUSAMY
Owner TEKMIRA PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products